The study purpose is to observe which neoadjuvant chemotherapy regimens is the better for invasive breast cancer. The neoadjuvant chemotherapy regimen is sustained anthracyclines plus taxanes or from anthracyclines plus taxanes to vinorelbine plus cisplatinum.

The investigators hope to get preliminary results for the breast cancer patients who are given different neoadjuvant chemothetapy regimens. The patients are randomized two chemotherapy regimens. One is anthracyclines plus taxanes for 6-8 cycles,the other is anthracyclines plus taxanes for 3-4 cycles ,then switch tovinorelbine plus cisplatinum for 3-4 cycles.

Inclusion Criteria:

• Diagnosis of invasive ductal or lobular breast cancer.

• Previously untreated (no chemotherapy or hormonal therapy or radiation therapy) invasive breast cancer.

• no anti-Her2 therapy if HER2 positive ( defined as 3+ IHC or FISH positive)

• Performance Status ECOG <2

• Age > 18 years

• Tumor > 2.0 cm by MRI and/or sonographic or clinical exam measurements.or Karnofsky >50%

• Lab test :

  • Absolute neutrophil count > 1,500/mm3

    • Total Bilirubin ≤ 2×ULN
    • AST and ALT ≤ 2.5×ULN

  • serum creatinine ≤ 1.5×ULN

Exclusion Criteria:

• Pregnant or breast feeding patients are excluded
• stage Ⅳ breast cancer
• History of non-breast malignancies within the 5 years prior to study entry, except for the following: carcinoma in situ of the cervix, carcinoma in situ of the colon,melanoma in situ, and basal cell and squamous cell carcinomas of the skin
• uncontrolled cardiac disease
• Active infection or chronic infection requiring chronic suppressive antibiotics
• History of hypersensitivity reaction to investigating drugs

diaganosis of invasive breast cancer, tumor size > 2.0cm by MRI or ultrasound or clinical examination.